Anifrolumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Anifrolumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetInterferon α/β receptor
Clinical data
Routes of
administration
Intravenous
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6444H9964N1712O2018S44
Molar mass145.12 kg/mol g·mol−1

Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus (SLE).[2] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.

The drug was developed by MedImmune, a unit of AstraZeneca, which chose to move anifrolumab instead of sifalimumab into phase III trials for lupus in 2015.[3][4][5]

Clinical trial results[edit]

Anifrolumab failed to meet its endpoint of significant reduction in disease as assessed by the SLE Responder Index 4 instrument in the TULIP 1 phase III trial[6]. This multi-center, double-blind, placebo-controlled study followed adults with moderate to severe SLE over the course of one year. Preliminary results were announced on 31 August 2018.

Adverse effects[edit]

The most common adverse effect was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.[7]

References[edit]

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association.
  3. ^ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017.
  4. ^ "Anifrolumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.
  5. ^ "Anifrolumab". AdisInsight. Retrieved 31 July 2017.
  6. ^ "Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus". www.astrazeneca.com. Retrieved 2019-02-05.
  7. ^ H. Spreitzer (29 August 2016). "Neue Wirkstoffe - Anifrolumab". Österreichische Apothekerzeitung (in German) (18/2016).